随机化和统计功效：试验可重复性的关键（即使对于罕见癌症也是如此）。
Randomization and statistical power: paramount in trial reproducibility (even for rare cancers).
机构信息
D.O., Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, 24 Frank Lloyd Wright Drive, Ann Arbor, Michigan 48106, USA.
出版信息
Oncologist. 2012;17(9):1129-32. doi: 10.1634/theoncologist.2012-0209. Epub 2012 Aug 22.
Abstract
This article comments on the importance of randomization and statistical power in clinical trials.
摘要
本文评论了随机化和临床试验统计功效的重要性。
相似文献
1
Randomization and statistical power: paramount in trial reproducibility (even for rare cancers).随机化和统计功效：试验可重复性的关键（即使对于罕见癌症也是如此）。
Oncologist. 2012;17(9):1129-32. doi: 10.1634/theoncologist.2012-0209. Epub 2012 Aug 22.
2
Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model.在一个可成像的患者来源原位异种移植（iPDOX）模型中，吉西他滨和多西他赛联合使用可抑制胃平滑肌肉瘤的增殖和侵袭。
Cell Cycle. 2017 Jun 3;16(11):1063-1069. doi: 10.1080/15384101.2017.1314406. Epub 2017 Apr 20.
3
Locally advanced leiomyosarcoma of the urinary bladder: near-complete pathologic response to neoadjuvant gemcitabine and docetaxel.
Anticancer Drugs. 2007 Jul;18(6):745-7. doi: 10.1097/CAD.0b013e32805f8f0c.
4
Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).吉西他滨单药对比吉西他滨联合多西他赛治疗转移性或复发性平滑肌肉瘤患者的多中心、分层随机二期研究：法国癌症中心联合会（FNCLCC）肉瘤协作组研究（TAXOGEM 研究）。
Oncologist. 2012;17(9):1213-20. doi: 10.1634/theoncologist.2011-0467. Epub 2012 Aug 20.
5
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.吉西他滨与多西他赛治疗不可切除平滑肌肉瘤患者：一项II期试验结果
J Clin Oncol. 2002 Jun 15;20(12):2824-31. doi: 10.1200/JCO.2002.11.050.
6
Primary Cardiac Leiomyosarcoma: A 27-Month Survival with Surgery and Chemotherapy.原发性心脏平滑肌肉瘤：手术及化疗后存活27个月
Intern Med. 2017 Aug 15;56(16):2145-2149. doi: 10.2169/internalmedicine.6965-15. Epub 2017 Aug 1.
7
Gemcitabine/docetaxel--welcome to a new standard.吉西他滨/多西他赛——迎来新标准。
Gynecol Oncol. 2008 Jun;109(3):313-5. doi: 10.1016/j.ygyno.2008.04.025.
8
Novel approaches to treatment of leiomyosarcomas.治疗平滑肌肉瘤的新方法。
Curr Oncol Rep. 2011 Aug;13(4):316-22. doi: 10.1007/s11912-011-0173-0.
9
Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan.吉西他滨联合多西他赛用于日本晚期或复发性子宫平滑肌肉瘤及未分化子宫内膜肉瘤的可行性研究。
Int J Clin Oncol. 2014 Oct;19(5):897-905. doi: 10.1007/s10147-013-0627-5. Epub 2013 Oct 24.
10
Adult primary pleomorphic leiomyosarcoma of forearm with axillary lymph node metastasis: a case report and literature review.
J Cancer Res Ther. 2012 Jul-Sep;8(3):448-50. doi: 10.4103/0973-1482.103532.
引用本文的文献
1
An Evaluation of Rare Cancer Policies in Europe: A Survey Among Healthcare Providers.欧洲罕见癌症政策评估：医疗服务提供者调查
Cancers (Basel). 2025 Jan 7;17(2):164. doi: 10.3390/cancers17020164.
2
Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures.保加利亚罕见癌症孤儿药的可及性与获取情况：延误及公共支出分析
Cancers (Basel). 2024 Apr 12;16(8):1489. doi: 10.3390/cancers16081489.
3
Design analysis indicates Potential overestimation of treatment effects in randomized controlled trials supporting Food and Drug Administration cancer drug approvals.设计分析表明，支持美国食品和药物管理局批准癌症药物的随机对照试验中，治疗效果可能被高估。
J Clin Epidemiol. 2018 Nov;103:1-9. doi: 10.1016/j.jclinepi.2018.06.012. Epub 2018 Jul 2.
本文引用的文献
1
Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).吉西他滨单药对比吉西他滨联合多西他赛治疗转移性或复发性平滑肌肉瘤患者的多中心、分层随机二期研究：法国癌症中心联合会（FNCLCC）肉瘤协作组研究（TAXOGEM 研究）。
Oncologist. 2012;17(9):1213-20. doi: 10.1634/theoncologist.2011-0467. Epub 2012 Aug 20.
2
Drug development: Raise standards for preclinical cancer research.药物研发：提高临床前癌症研究标准。
Nature. 2012 Mar 28;483(7391):531-3. doi: 10.1038/483531a.
3
Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.Ewing 肉瘤、骨肉瘤或不可切除或局部复发性软骨肉瘤的吉西他滨序贯多西他赛治疗的 II 期研究：肉瘤合作研究联盟研究 003 的结果。
Oncologist. 2012;17(3):321. doi: 10.1634/theoncologist.2010-0265. Epub 2012 Feb 23.
4
Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.临床肿瘤进展 2011：美国临床肿瘤学会癌症进展年度报告。
J Clin Oncol. 2012 Jan 1;30(1):88-109. doi: 10.1200/JCO.2011.40.1919. Epub 2011 Dec 5.
5
Outcome--adaptive randomization: is it useful?结局适应性随机化：它有用吗？
J Clin Oncol. 2011 Feb 20;29(6):771-6. doi: 10.1200/JCO.2010.31.1423. Epub 2010 Dec 20.
6
Adaptive clinical trials: the promise and the caution.适应性临床试验：前景与警示。
J Clin Oncol. 2011 Feb 20;29(6):606-9. doi: 10.1200/JCO.2010.32.2685. Epub 2010 Dec 20.
7
Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study.吉西他滨固定剂量率用于晚期软组织肉瘤患者：一项单中心II期研究。
Cancer Chemother Pharmacol. 2008 Dec;63(1):149-55. doi: 10.1007/s00280-008-0723-9. Epub 2008 Mar 20.
8
Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future.吉西他滨和多西他赛用于转移性肉瘤：过去、现在与未来
Oncologist. 2007 Aug;12(8):999-1006. doi: 10.1634/theoncologist.12-8-999.
9
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].吉西他滨与多西他赛联合用药对比吉西他滨单药治疗转移性软组织肉瘤患者的随机II期研究：肉瘤协作研究联盟002研究结果[校正后]
J Clin Oncol. 2007 Jul 1;25(19):2755-63. doi: 10.1200/JCO.2006.10.4117.
10
Practical Bayesian adaptive randomisation in clinical trials.临床试验中的实用贝叶斯自适应随机化
Eur J Cancer. 2007 Mar;43(5):859-66. doi: 10.1016/j.ejca.2007.01.006. Epub 2007 Feb 16.
Zotero 插件